Patents by Inventor Alastair Rae

Alastair Rae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20230391773
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 16, 2023
    Publication date: December 7, 2023
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Plasma Kallikrein inhibitors and uses thereof
    Patent number: 11787796
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20230078513
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 16, 2023
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20220298176
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 11370803
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210079022
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20210078999
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20200317667
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 10730874
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: August 4, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20190284182
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 19, 2019
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Amino-substituted heterocyclic derivatives as sodium channel inhibitors
    Patent number: 10214509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 26, 2019
    Assignee: Almirall, S.A.
    Inventors: James Duffy, Mark Stuart Chambers, Alastair Rae, James Osborne, Isabelle Anne Lemasson, Michael Daniel Goldsmith, Andrew Sharpe, Silvia Fonquerna Pou
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20180289718
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Fused imidazole compounds
    Patent number: 10016439
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 10, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji Saito, Masato Higashino, Soichi Kawaharada, Arwel Lewis, Mark Stuart Chambers, Alastair Rae, Kim Louise Hirst, Charles David Hartley
  • AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS
    Publication number: 20180105509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Application
    Filed: April 20, 2016
    Publication date: April 19, 2018
    Inventors: James DUFFY, Mark Stuart CHAMBERS, Alastair RAE, James OSBORNE, Isabelle Anne LEMASSON, Michael Daniel GOLDSMITH, Andrew SHARPE, Silvia FONQUERNA POU
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20160331757
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 17, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Novel compounds useful for the treatment of degenerative & inflamatory diseases
    Publication number: 20090137549
    Abstract: The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.
    Type: Application
    Filed: November 8, 2007
    Publication date: May 28, 2009
    Inventors: Paul John Edward, Mark Stuart Chambers, Christel Jeanne Marie Menet, Stephen Robert Fletcher, Rebecca Elizabeth Jarvis, Herve Van De Poel, Alexander Sudau, Alastair Rae, Peter Stanley Thomas